When it comes to shaping economic reforms, the true measure lies not in policy announcements but in the real impact they create. The government’s latest move to rationalise GST rates represents one of the most patient-centric and strategic adjustments yet, signalling a clear commitment to make healthcare more affordable for every Indian.
The Indian pharmaceutical industry has been a vital partner in advancing the government’s vision of affordable and accessible healthcare. As the world’s leading supplier of generic drugs, it has ensured life-saving medicines are available at competitive costs, supporting domestic and global health demands. From backing national health programmes to strengthening manufacturing and innovation, the pharma industry has complemented policy goals.
For over five decades, Alkem has been a part of India’s pharmaceutical transformation with a core purpose of making high-quality medicines affordable and more accessible to people. The Indian pharma market, sized INR 2 lakh crore, has grown at a CAGR of 8% in the last five years, and Alkem has a share of 4% in the pharma market. With its strong distribution network, the company has been working towards meeting the healthcare needs of the country and has gained the trust of healthcare providers as well as patients.
Alkem expresses gratitude to the Honourable Prime Minister Narendra Modi and Honourable Finance Minister Nirmala Sitharaman for undertaking the landmark GST reforms and remains aligned with the government’s vision of universal, affordable and accessible healthcare.
The new tax changes, which include reduction of GST from 12% to nil on 33 lifesaving drugs for cancer, rare diseases and chronic conditions, from 5% to nil on three cancer drugs, and from 12% to 5% on all the medicines and nutraceuticals, benefits the common man by bringing down out-of-pocket expenses and reinforces Alkem’s mission of widening access to quality medicines.
GST exemption also strengthens the insurance ecosystem. Lower treatment costs reduce claim burdens, enabling policies to offer broader coverage for advanced or long-term therapies. Together, pricing changes and insurance uptake create a stronger and more sustainable healthcare framework.
Additionally, moving most goods into standard 5 % or 18 % brackets simplifies compliance, while trust-based provisional refunds of up to 90 % on inverted duty structures and seamless input-tax credit on discounts ease working-capital pressure. These shifts enable companies to invest more deeply in innovation. Also, place-of-supply rules allow pharma R&D services to qualify more easily for export benefits.
By working closely with the government, healthcare providers, insurers, and distribution partners, Alkem is committed to ensuring that the revised prices and benefits reach patients seamlessly and swiftly.
More Special Features on www.mediaeyenews.com
